Want to see CH:KURN full AI Analyst Report?
Top Page
Kuros Biosciences
(KURN)
Select Model
Select Model
Rating:59Neutral
Price Target:
CHF24.50
▲(23.74% Upside)
Action:Reiterated
Date:07/30/26
The score is driven primarily by solid underlying business progress and a conservative balance sheet, but is held back by weak cash flow conversion in 2025 and an extremely high P/E that leaves little margin for error. Technically, the setup is improving in the short term but not yet strong on a long-term basis (still below the 200-day average).
Positive Factors
Revenue Growth
Sustained multi-year revenue expansion shows the business is scaling commercial adoption and procedure-driven demand. Continued top-line growth provides a durable runway to leverage fixed costs, support R&D and sales expansion, and reduce per-unit costs over the next 2–6 months.
Negative Factors
Weak Cash Conversion
Despite accounting profits in 2025, negative operating and free cash flow signal working-capital or investment drains. Persistent negative cash conversion raises near-term funding needs and could force external financing or slow commercial programs if not reversed.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Sustained multi-year revenue expansion shows the business is scaling commercial adoption and procedure-driven demand. Continued top-line growth provides a durable runway to leverage fixed costs, support R&D and sales expansion, and reduce per-unit costs over the next 2–6 months.
Read all positive factors
Kuros Biosciences (KURN) vs. iShares MSCI Switzerland ETF (EWL)
Market Cap
CHF894.14M
Dividend YieldN/A
Average Volume (3M)128.87K
Price to Earnings (P/E)531.9
Beta (1Y)1.39
Revenue Growth59.85%
EPS GrowthN/A
CountryCH
Employees178
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.04
Shares Outstanding39,458,786
10 Day Avg. Volume110,510
30 Day Avg. Volume128,868
Financial Highlights & Ratios
PEG Ratio-3.21
Price to Book (P/B)15.78
Price to Sales (P/S)8.71
P/FCF Ratio-439.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF32.50Price Target Upside64.14% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.31
Revenue Forecast (FY)CHF207.75M
Kuros Biosciences Business Overview & Revenue Model
Company Description
Kuros Biosciences AG functions as a biopharmaceutical enterprise, dedicated to both the development and market introduction of advanced therapeutic solutions for tissue regeneration and bone repair. Its operations span across the United States, th...
How the Company Makes Money
Kuros primarily makes money by selling its synthetic bone graft products (notably MagnetOs) to hospitals and surgical centers for use in procedures such as spinal fusion and other bone repair applications. Revenue is generated from product sales v...
Kuros Biosciences Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
82
Very Positive
Cash Flow
46
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 121.30M | 75.56M | 33.56M | 17.99M | 13.81M |
| Gross Profit | 104.79M | 62.03M | 23.94M | 10.77M | 10.07M |
| EBITDA | 10.13M | -561.00K | -6.84M | -8.84M | -5.29M |
| Net Income | 2.12M | -3.72M | -13.73M | -14.60M | -7.54M |
Balance Sheet | |||||
| Total Assets | 107.21M | 84.54M | 71.46M | 82.95M | 91.34M |
| Cash, Cash Equivalents and Short-Term Investments | 15.66M | 17.46M | 14.21M | 24.07M | 28.62M |
| Total Debt | 3.94M | 1.79M | 2.14M | 1.91M | 8.93M |
| Total Liabilities | 40.28M | 25.79M | 14.75M | 14.09M | 14.36M |
| Stockholders Equity | 66.93M | 58.75M | 56.71M | 68.86M | 76.98M |
Cash Flow | |||||
| Free Cash Flow | -2.40M | 2.03M | -9.17M | -7.75M | -5.83M |
| Operating Cash Flow | -377.87K | 3.14M | -8.84M | -7.35M | -5.45M |
| Investing Cash Flow | -2.03M | -1.11M | -326.00K | -400.00K | -374.00K |
| Financing Cash Flow | 1.17M | 1.34M | -171.00K | 3.22M | 6.08M |
Kuros Biosciences Technical Analysis
Positive
19.80
Price Trends
20.32
Positive
21.33
Positive
24.57
Negative
Market Momentum
0.83
Negative
62.07
Neutral
71.23
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:KURN, the sentiment is Positive. The current price of 19.8 is below the 20-day moving average (MA) of 21.53, below the 50-day MA of 20.32, and below the 200-day MA of 24.57, indicating a neutral trend. The MACD of 0.83 indicates Negative momentum. The RSI at 62.07 is Neutral, neither overbought nor oversold. The STOCH value of 71.23 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CH:KURN.
Kuros Biosciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | CHF637.71M | 19.58 | ― | ― | 11.43% | -48.80% | |
59 Neutral | CHF894.14M | 531.92 | 2.28% | ― | 59.85% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | CHF242.60M | -18.58 | 277.88% | ― | -63.05% | -187.61% | |
45 Neutral | CHF1.60B | -4.67 | ― | ― | -8.06% | -87.00% | |
44 Neutral | CHF210.06M | -3.71 | 684.83% | ― | 97.32% | -11.07% | |
43 Neutral | CHF134.45M | -2.13 | -66.19% | ― | -100.00% | 9.23% |
* Healthcare Sector Average
CH:KURN
Kuros Biosciences
23.06
-3.70
-13.83%
CH:MOLN
Molecular Partners AG
3.24
0.38
13.09%
CH:BSLN
Basilea Pharmaceutica
51.80
0.10
0.19%
CH:IDIA
Idorsia Ltd
6.01
3.39
129.20%
CH:NWRN
Newron Pharmaceuticals SpA
12.22
4.48
57.88%
CH:SANN
Santhera Pharmaceuticals Holding
15.84
2.70
20.55%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.